Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)

Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)

5-Minute Journal Club — ASH 2010 Presentations

Please click each issue for edition topic links.

ASH Highlights: MDS 2011 — The Future Ain't What It Used to Be
Issue 8 — March 29, 2011 — Current Edition

Go directly to our slides and commentary on:

Tolerance and Response to Initial Systemic Therapy in Younger and Older Patients with Multiple Myeloma: A Cross-Sectional Case Survey with 276 Unselected Recent Cases in the Practices of US-Based Medical Oncologists

Tolerance and Response to Initial Systemic Therapy in Younger and Older Patients with Multiple Myeloma: A Cross-Sectional Case Survey with 276 Unselected Recent Cases in the Practices of US-Based Medical Oncologists.
N Love, MD; S Lonial, MD; K Anderson, MD; R Fonseca, MD; K Ziel, PhD; M Elder, BBA; D Paley, BA; A Asnis-Alibozek, MPAS, PA-C

Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)

Bortezomib-Based Maintenance Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma (MM)

Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (MM) or MM in the Post-TransplantSetting

Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)

Module III: Dr Robert Dreicer

Cancer Educators Slide Library: Management of Dermatologic Toxicities

Module II: Dr Stephen Freedland

PCUTT — Module I: Dr Judd W Moul

Subscription | Cancel Subscription Request

Please fill out the form below if you no longer wish to receive our printed material. Allow four to six weeks processing time to have your subscription canceled.

To subscribe to our programs, click here.

Monday Night with Research To Practice: Seminar VIII — Advanced Prostate Cancer

Monday Night with Research To Practice: Seminar VII — Diffuse Large B-Cell Lymphoma (DLBCL)/T-Cell Lymphomas (TCL)/Mantle-Cell Lymphoma (MCL)

Syndicate content